Construction and characterization of a t-PA mutant for use in ATTEMPTS: A drug delivery system for achieving targeted thrombolysis

Journal of Controlled Release

Volumn 110, Issue 1, 2005, Pages 164-176

  Yang, Victor C ^a,b   Naik, Sarita S ^b   Song, Hui ^b   Dombkowski, Alan A ^c   Crippen, Gorden ^b   Liang, Jun F ^d  

^a TIANJIN UNIVERSITY   (China)

^b UNIVERSITY OF MICHIGAN   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d Stevens Institute of Technology   (United States)

Author keywords

ATTEMPTS; Heparin; Prodrug; Protamine; Targeted delivery; Tissue type plasminogen activator

Indexed keywords

PRODRUG; TARGETED DELIVERY; TISSUE-TYPE PLASMINOGEN ACTIVATOR;

ANTIBODIES; BIOASSAY; COAGULATION; COMPUTER SIMULATION; ENZYME INHIBITION; POSITIVE IONS; PROTEINS;

DRUG DOSAGE;

AMINO ACID; ANTIBODY; ARGININE; BLOOD CLOTTING FACTOR; CHROMOGENIC SUBSTRATE; CYSTEINE; FIBRIN TARGETING ANTIBODY; GLUTAMIC ACID; GLYCINE; HEPARIN; HEPARIN BINDING PROTEIN; LYSYLHISTIDYLARGINYLARGINYLCYSTEINYLPROLYLARGINYLARGINYLARGININE; PEPTIDE; PLASMINOGEN; PROTAMINE; PROTEIN; SERINE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

AMINO ACID COMPOSITION; AMINO ACID SEQUENCE; ANIMAL CELL; ANTIBODY TARGETED TRIGGERED ELECTRICALLY MODIFIED PRODRUG TYPE STRATEGY; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BLOOD CLOTTING; COMPUTER SIMULATION; CONJUGATION; DRUG DELIVERY SYSTEM; ENZYME ACTIVITY; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; GENETIC ENGINEERING; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION;

ANIMALS; BASE SEQUENCE; BINDING SITES; CHO CELLS; COMPUTER SIMULATION; CRICETINAE; DRUG DELIVERY SYSTEMS; DRUG DESIGN; FIBRINOLYTIC AGENTS; HEPARIN; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; MUTATION; PRODRUGS; RECOMBINANT PROTEINS; TISSUE PLASMINOGEN ACTIVATOR; TRANSFECTION;

ANTIBODIES; CATIONS; COAGULATION; DRUGS; ENZYMES; PROTEINS; SIMULATION;

EID: 28244485412     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2005.09.027     Document Type: Article

References (19)

1. D. Collen, and H. Lijnen G. Stamatoyannopoulos A.W. Nienhuis P.W. Majerus H. Varmus The Molecular Basis of Blood Diseases 1994 W.B. Saunders Co. Philadelphia 725 752
2. E. Haber, T. Quertermous, G.R. Matsueda, and M.S. Runge Innovative approaches to plasminogen activator therapy Science 243 1989 51 56
3. J.I. Weitz, R.J. Stewart, and J.C. Fredenburgh Mechanism of action of plasminogen activators Thromb. Haemost. 82 2 1999 974 982
4. J.-F. Liang, Y. Li, M.E. Connell, and V.C. Yang Synthesis and characterization of positively charged tPA as a prodrug using a heparin/protamine-based drug delivery system AAPS Pharmsci. 2 1 2000 (Article 7)
5. J.-F. Liang, Y. Li, H. Song, Y.-J. Park, S.S. Naik, and V.C. Yang ATTEMPTS: a heparin/protamine-based delivery system for enzyme drugs J. Control. Release 78 2002 67 79
6. Y.-J. Park, J.-F. Liang, H. Song, Y. Li, S.S. Naik, and V.C. Yang ATTEMPTS: a heparin/protamine-based triggered release system for the delivery of enzyme drugs without associated side-effects Adv. Drug Delivery Rev. 55 2003 251 265
7. S.S. Naik, J.-F. Liang, Y.-J. Park, W.-K. Lee, and V.C. Yang Application of ATTEMPTS for drug delivery J. Contr. Rel. 10 2005 34 45
8. A.D. Cardin, and H.R. Weintraub Molecular modeling of protein-glycosaminoglycan interactions Arteriosclerosis 9 1989 21 32
9. R.J. Kaufman, L.C. Wasley, A.J. Spiliotes, S.D. Gossels, S.A. Latt, G.R. Larsen, and R.M. Kay Coamplification and coexpression of human tissue-type plasminogen activator and murine dihydrofolate reductase sequences in Chinese hamster ovary cells Mol. Cell. Biol. 5 7 1985 1750 1759
10. J. Verheijen, E. Mullaart, G. Chang, C. Kluft, and G. Wijngaards A simple, sensitive spectrophotometric assay for extrinsic (tissue type) plasminogen activator applicable to measurements in plasma Thromb. Haemost. 48 3 1982 266 269
11. A. Granelli-Piperno A study of proteases and protease-inhibitor complexes in biological fluids J. Exp. Med. 148 1 1978 223 234
12. L.-C. Chang Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (I): preparation and characterization AAPS Pharmsci. 3 3 2001
13. G. Urlaub, and L.A. Chasin Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity Proc. Natl. Acad. Sci. 77 1980 4216 4220
14. T.H. Nguyen, and C. Ward Stability characterization and formulation development of alteplase, a recombinant tissue plasminogen activator Pharm. Biotechnol. 5 1993 91 134
15. E.L. Madison, E.J. Goldsmith, R.D. Gerard, M.-J.H. Gething, J.F. Sambrook, and R.S. Bassel-Duby Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1 Proc. Natl. Acad. Sci. 87 1990 3530 3533
16. S.A. Marshall, G.A. Lazar, A.J. Chirino, and J.R. Desjarlais Rational design and engineering of therapeutic proteins DDT 8 5 2003 212 221
17. I.C. MacDougall Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients J. Am. Soc. Nephrol. 10 1999 2392 2395
18. L. Lin Betaseron Dev. Biol. Stand. 96 1998 97 104
19. Y. Byun, V.K. Singh, and V.C. Yang Low molecular weight protamine: a potential nontoxic heparin antagonist Thromb. Res. 94 1999 53 61